The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents the first interim results of the MajesTEC-3 trial (NCT05083169), a Phase III randomized study comparing teclistamab plus daratumumab (Tec-Dara) to investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received 1–3 prior lines of therapy. Dr Costa notes that the safety and efficacy data to date are highly encouraging and believes that Tec-Dara may represent a new standard of care in myeloma from the second-line setting and beyond. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
